Notably, the co-administration of the GLP-1 receptor agonist and GIP in mice with T2DM and obesity showed a greater improvement in glycemic and body weight than with selective GLP-1 receptor agonists [23]. Here, GLP1R is linked to type 2 diabetes mellitus.